Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging - Wikidata - awgldk - TriplyDB

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

http://www.wikidata.org/entity/Q34032208

about

Iron chelation therapy in myelodysplastic syndromes: where do we stand?Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.Iron chelation therapy in myelodysplastic syndromes.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Dual Action of Myricetin on Porphyromonas gingivalis and the Inflammatory Response of Host Cells: A Promising Therapeutic Molecule for Periodontal Diseases.Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.TfR1 interacts with the IKK complex and is involved in IKK-NF-κB signalling Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.Efficacy and safety of deferasirox in myelodysplastic syndromes.Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.Iron chelation in the treatment of cancer: a new role for deferasirox?An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.Deferasirox in a refractory anemia after other treatment options: case report and literature review.Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.The potential of deferasirox as a novel therapeutic modality in gastric cancer Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines.The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Acute Liver Failure in a Pediatric Patient with Congenital Dysery-Thropoietic Anemia Type I Treated with Deferasirox.Deferasirox reduces oxidative stress in patients with transfusion dependency.Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis Effects of oral iron chelator deferasirox on human malignant lymphoma cells.Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice.Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?

P2860

Q27011747-EB3D00ED-8A88-4165-BCB6-F57E8E4EAEED Q33829550-43953316-53DE-4820-86FB-4C9B22F3DCD4 Q34002840-A29C5C63-5B3D-48BD-8837-24FCC921D4C6 Q34220013-445931A7-3912-4258-A05B-63A98D2FE082 Q34804866-AE0A4DD9-5BA1-40EA-8238-CB12186DF0BE Q35414429-8775C0BD-43B4-4848-9B29-4091B5536C5E Q35677062-A58700DB-16E2-4992-94F9-79A3A8E6415F Q35911202-D5EA572C-E2F7-4A5D-9C98-EFCF9F754193 Q36216214-DABFE871-F04B-49A6-91E3-1C20889AE329 Q36509188-6429B5F4-A021-4ACE-99F1-636B2E565DC7 Q36681744-F6F2536A-51A1-4D64-BDA2-30B4A5EB1A48 Q36862483-745B94D6-D530-4C81-AD25-1D3180CB75B4 Q37326129-373BFCA2-ED46-4E88-A902-5CD194A0F6C1 Q37665665-E6EC4C81-B89B-4865-86D7-076A671F348E Q37849630-72E7990C-EC42-4EDE-B57E-CC69507A4708 Q38082464-326A9CA1-EB62-4BD1-8D8F-6CD84FF5C976 Q38101043-4565B32B-115F-42A3-97C4-53712880FCCB Q38112400-5359D31D-4A5D-4DB8-B851-E58397D2EAA4 Q38368123-63A8B001-7E40-4FE4-98B8-85F6EF27ECA5 Q38427850-2818C9E6-B54A-485E-A3DE-2878A2B7620D Q38549248-C424DE9B-D994-49B7-8AF1-102B1045318A Q38710822-25006ED7-ACCB-4787-A7B6-0FE45702A1CC Q38763826-53F9D32D-7B0F-4D66-A1AC-223D2372183E Q38787167-EA7ACEB6-DCB0-40DF-88EC-3A3057E67261 Q38832241-5C53EA45-B237-4E92-82FF-032A31964C75 Q38892236-9736EC88-B850-48E5-A084-672A7B3F8148 Q38951695-79BADB09-C039-4158-B915-EBA6729A55FA Q39269756-DB2DCAC7-3537-4FAE-8D6E-B837979E5723 Q40210444-EF5B2233-DC71-4615-B6BE-299C6BCB44D1 Q40334567-C648965F-B023-4500-8A59-6E90CC9E0CDB Q40639096-450EF038-023A-4A14-9F9B-6EF1E6E1F911 Q40892218-AF54BB3E-AB9A-4D81-B760-677965F7B4B3 Q41468470-5B5DBA42-80C5-44D9-B7C1-1BA078925933 Q41773526-B5ABC87E-07FD-4AEE-811A-77DC14D35A25 Q41980585-D17D7266-59EE-40A1-A11A-8BFD8C5C7949 Q42233318-58A5DC62-711B-4D1F-9B9B-8BEC4528C96F Q42645802-1A3C1A3E-35D1-406E-9A2A-9232BC7E3352 Q43459542-0351FBBA-0FE0-4F0B-81E0-BACC5D7D531A Q43934706-FA2D455A-B77B-48CD-9C64-5747CBEECC4B Q45971495-B9142C3E-3E29-4271-BF48-47308E514F82

P2860

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

http://www.wikidata.org/entity/Q34032208

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@ast

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@en

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@nl

type

label

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@ast

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@en

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@nl

prefLabel

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@ast

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@en

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@nl

P1433

Q34032208-3CCD1801-6518-4253-8F38-99F28EFF48BB

P1476

Q34032208-A37D0C68-3DAA-4083-9F08-7212C5D76B0D

P2093

Q34032208-0C6BC50E-F682-4318-916A-E9C74B7A6018

Q34032208-1F64D38B-327F-4045-9554-710F0A9DB6A2

Q34032208-3300DD24-22CD-4872-BB04-99880B9DDCC7

Q34032208-426128BC-6F24-40E1-89FE-6405BA5CBCB6

Q34032208-4FE97BCE-E3B5-41EC-9A83-EAA4EC9AAC18

Q34032208-6DD5089E-7D95-4CC6-BF54-FF85C2A53E74

Q34032208-7A2A3EF8-8137-435D-BDA6-2A66238DC02E

Q34032208-8B6EC231-ADB6-42E0-9011-F5AB86B79891

Q34032208-B391F3CD-FA3E-4D84-81DD-1DDE44588AF9

Q34032208-B6BB93DA-EDFA-4D3D-A602-C035F5CB7475

P2860

Q34032208-0062CC61-6179-4A07-88A1-CFF95AD72BE5

Q34032208-03A8D581-42C1-4D38-9A39-CE1857BBB857

Q34032208-0F1B29A0-03F4-44FA-8630-FEA854A484D9

Q34032208-140A3223-ECB8-43D8-AC56-7172613E0048

Q34032208-1E892474-DE2B-4A76-A5CD-1D2DB6A2E8DB

Q34032208-20D98C74-B018-41C8-B1A2-9AE93D0F02F1

Q34032208-31DD71E8-B71E-4856-8409-11CA4D5CE754

Q34032208-3601A9DB-CDE1-465F-8EF7-512B9771334E

Q34032208-39502CC4-51CA-441E-8C65-3DD25DFD3977

Q34032208-3AFB5E1E-031C-45E3-9377-E1F70D133F1A

P304

Q34032208-0B5BABC9-5333-4229-A9C4-36A876031C4E

P31

Q34032208-52A77843-773E-4FA7-BDAC-89CF427C40A6

P356

Q34032208-74A599AA-FE49-47F3-B4A4-4C7BDA85B4DD

P433

Q34032208-24DB6685-74BE-4D84-99FB-4F4994E6AE7D

P478

Q34032208-B5310366-BB74-4845-BF10-E5627787373F

P50

Q34032208-ACC41AFF-A52E-41B2-854B-5001C08516BA

Q34032208-DB110182-C6C8-4866-B350-17EE131234B3

Q34032208-FEE4EACA-8504-4663-AFEE-BC0FCBE63420

P577

Q34032208-DD46D19B-3DB1-4D79-BCDF-EA26849D4B6C

P5875

Q34032208-25C135DC-3B7A-4CD7-A400-28675D47A395

P698

Q34032208-63A7EBA9-0C36-478B-9ED2-C6906D8E1603

P921

Q34032208-99D9E837-1629-48F4-88DA-6EC6032F4E5D

P932

Q34032208-54CA2115-E671-44EA-B8AA-FE05C05BA749

P356

HAEMATOL.2009.016824

P1433

P1476

Deferasirox is a powerful NF-k ...... tive oxygen species scavenging

@en

P2093

Antonia Rotolo

http://www.w3.org/2001/XMLSchema#string

Chiara Maffè

http://www.w3.org/2001/XMLSchema#string

Chiara Zanone

http://www.w3.org/2001/XMLSchema#string

Daniela Cilloni

http://www.w3.org/2001/XMLSchema#string

Daniele Alberti

http://www.w3.org/2001/XMLSchema#string

Elisabetta Greco

http://www.w3.org/2001/XMLSchema#string

Emanuela Messa

http://www.w3.org/2001/XMLSchema#string

Enrico Bracco

http://www.w3.org/2001/XMLSchema#string

Francesca Messa

http://www.w3.org/2001/XMLSchema#string

Ilaria Defilippi

http://www.w3.org/2001/XMLSchema#string

P2860

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation

International scoring system for evaluating prognosis in myelodysplastic syndromes

Shared principles in NF-kappaB signaling

NF-kappaB in cancer: from innocent bystander to major culprit

The death domain kinase RIP mediates the TNF-induced NF-kappaB signal

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.

Iron regulation of hepatic macrophage TNFalpha expression.

The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.

P304

1308-1316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2009.016824

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Arruga

Giuseppe Saglio

Antonella Roetto

P577

2010-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44660309

http://www.w3.org/2001/XMLSchema#string

P698

20534700

http://www.w3.org/2001/XMLSchema#string

P921

P932

2913079

http://www.w3.org/2001/XMLSchema#string